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In order to explore the relationship between different antibiotic dosing regimens and
selective enrichment of resistant strains, tissue-cage infection model was established in
rabbits to study relationship between cefquinome pharmacokinetic/pharmacodynamic
parameters and the change of susceptibility of Staphylococcus aureus (S. aureus). In
this model, above 108 CFU/mL of S. aureus culture were exposed to cefquinome
concentrations below the MIC99 (the minimal concentration that inhibits colony
formation by 99% in vitro, 0.3 µg/mL), between the MIC99 and the MPC (the mutant
prevent concentration in vitro, 1.6 µg/mL), and above the MPC after intramuscular
injection with cefquinome at doses of 4, 8, 16, and 32 mg/kg of body weight (bw)
once daily for 5 days or 4, 8, 16, and 24 mg/kg of bw twice daily for 2.5 days.
Samples of tissue-cage fluid were collected from the tissue-cage at 2, 4, 6, 8, 10,
12, 24 h after each dosing (one dosing daily) or at 2, 4, 6, 8, 10, and 12 h (two
dosing daily). Cefquinome concentration, susceptibility of S. aureus to cefquinome, and
bacterial numbers at the infected site were monitored. The MICs of S. aureus and the
fraction of resistant bacteria both increased when cefquinome concentrations fluctuated
between the MIC99 and MPC. Resistant bacteria were selected in vivo when %T >MPC
was < 58% of administration interval or %T > MIC99 was ≥70% of administration
interval. These findings demonstrate that low-level, cefquinome-resistant S. aureus were
selected predominantly when drug concentrations fell inside a concentration window in
in vivo model, which was evidenced by pulsed-field gel electrophoresis. The selection of
resistant bacteria arose from both susceptible bacteria being killed and resistant bacteria
re-growth. Keeping drug concentrations above the MPC for ≥58% of administration
interval provides a strategy to achieve effective antibacterial activity and minimize the
emergence of resistance to cefquinome.
Keywords: Staphylococcus aureus, cefquinome, antimicrobial resistance, rabbit tissue-cage infection model,
PK/PD parameters
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INTRODUCTION
Cephalosporins, which are among the most important drugs,
are used to combat bacterial infections including those caused
by S. aureus in humans and animals. Cefquinome is a fourth-
generation cephalosporin, which was only used in veterinary
applications and approved for the treatment of acute mastitis
caused by S. aureus (Committee for Veterinary Medicinal
Products [CVMP], 2009). However, due to the overuse and
abuse of animal drugs, the selective enrichment of resistant
strains becomes a serious problem worldwide (Howard et al.,
2013) and will be a great threat to human health. In order to
prevent or lessen the emergence of resistant bacteria, it is of
great importance to explore the mechanism of selected resistant
strains under different dosing regimens and then optimize dosing
regimen.
Appropriate antibiotic dosing regimen is not only the key
to the eradication of infection-causing bacteria but also has an
important role in inhibiting the emergence and proliferation
of antibiotic-resistant strains (Toutain et al., 2002). One of
the approaches to restrict the acquisition of resistance is the
mutant selection window (MSW) hypothesis (Zhao and Drlica,
2001). The hypothesis offered a range of drug concentrations:
the lower boundary is MIC99 (the minimal concentration that
inhibits colony formation by 99%) and the upper boundary is
MPC (the mutant prevention concentration that inhibits growth
of the least-susceptible mutant subpopulation). Maintaining
concentrations outside the MSW can prevent the selection
of resistant bacteria. In addition, MIC- and MPC-related
pharmacokinetic/pharmacodynamic (PK/PD) parameters play
an important role in the application of the MSW hypothesis
to elucidate the development of resistance (Firsov et al.,
2003). The tissue-cage model was usually used to study the
PK/PD parameters because drug concentrations and the selective
amplification of resistant bacteria can be directly measured at
the infected site, and the in vivo model also simulates the
dynamic relationship among the antimicrobial agents, organism,
and pathogens (Craig, 1993; Fernandez et al., 1999).
In this study, a standard S. aureus was exposed to different
cefquinome dosing regimens in rabbit tissue-cage infection
model. Additionally, we examined the relationship between the
resistant strains and the original susceptible strain by pulsed-
field gel electrophoresis (PFGE). The purpose of the study
was to validate that resistant bacteria would be selected and
enriched predominantly when drug concentrations fell inside
a concentration window (MSW), the boundaries of which
determined by the agar dilution method.
MATERIALS AND METHODS
Antimicrobials and Chemicals
Cefquinome standard was provided by China Institute of
Veterinary Drugs Control (Beijing, PR China). Cefquinome
sulfate injection (Cobactan, the Batch Number A659A01) was
obtained from MSD Animal Health (Shanghai) Trading Co. Ltd.,
Penicillin, as a sodium salt for injection, was purchased from Jia
Tai Animal Pharmaceutical Co, Ltd., (Sichuan, China). Xylazine
hydrochloride injection was purchased from Shengda Animal
Pharmaceutical Co. Ltd (Jilin, China). Ketamine hydrochloride
injection was purchased from Hengrui Medicine Co. Ltd
(Jiangsu, China).
Bacterial Strain and Susceptibility
Testing
S. aureus ATCC 29213 was selected for the study. MIC of
cefquinome was determined by means of the agar dilution
method according to the Clinical and Laboratory Standards
Institute (CLSI) reference method (Clinical and Laboratory
Standards Institute [CLSI], 2013). The MIC of the strain in the
blank tissue-cage fluid was further measured by the broth micro-
dilution method. MIC99 and MPCs were determined using a
previously method (Lu et al., 2003). Briefly, for MIC99, serial
dilutions of stationary-phase cultures were applied to Mueller–
Hinton (MH) agar plates containing various drug concentrations.
After incubation at 37◦C for 24 h, bacterial colonies were
counted. The minimal concentration that inhibits growth of 99%
colonies was defined as MIC99.
For MPCs, series of MH agar plates containing known drug
concentrations were inoculated with above 1010 CFU S. aureus.
The inoculated plates were incubated at 37◦C for 72 h and
screened visually for growth. The preliminary MPC was taken as
the lowest drug concentration that prevented growth. To estimate
the exact MPC, logarithms of bacterial numbers were plotted
against antibiotic concentrations. The exact MPC was taken as
the point that intersected the theoretical limit of detection.
Rabbit Tissue-Cage Infection Model
Thirty-eight New Zealand White rabbits, three- to four-
month-old, weighing 2.5–3.2 kg, were supplied by Guangzhou
NanFang Medical Experimental Animal Science & Technology
Development Co. Ltd. They were kept individually in cages and
fed antibiotic-free food and water. The experimental protocol
was approved by the Committee on the Ethics of Animals of
South China Agricultural University (Approval number 2015-04;
March 11, 2015). Rabbits were anesthetized by use of xylazine
(4 mg/kg) and ketamine (40 mg/kg) intramuscularly (Cui et al.,
2006). Then a 5-cm incision was made in the dorsal middle of
each rabbit and an autoclaved plastic ball (Wiﬄe ball, 43 mm in
diameter, with a volume of 34 mL) was implanted subcutaneously
into each rabbit through the incision. The incision was closed
with sutures. After the surgery, the rabbits were injected with
penicillin intramuscularly (100,000 IU/kg) twice daily for 3 days
to prevent infection. About 4–6 weeks after implantation, the
Wiﬄe ball had been wrapped in a layer of connective tissue and
was full of clear, bright tissue-cage fluid. About 0.5 mL tissue-
cage fluid was collected from each plastic ball to confirm sterile
tissue-cage fluid. More than 1010 CFU of S. aureus culture in
the logarithmic growth phase were concentrated in 2 mL of 0.9%
NaCl solution and injected into each plastic ball. Two days after
infection, 0.5 mL tissue-cage fluid was removed from each plastic
ball for bacteria counting. Rabbits having above 108 CFU/mL
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bacterial concentration in tissue-cage fluid were treated with
cefquinome.
Dosing Regimens and Pharmacokinetic
Measurements
According to the results of the preliminary experiments, rabbits
were administered cefquinome at doses of 4, 8, 16, and 32 mg/kg
of bw once daily for 5 days or 4, 8, 16, and 24 mg/kg of bw
twice daily for 2.5 days. For treatment groups, cefquinome sulfate
injection was administrated intramuscularly, beginning at day 3
after infection. Control groups were injected with sterile normal
saline in the same way. About 0.5 mL sample of tissue-cage fluid
was collected from the plastic ball with a syringe at 2, 4, 6, 8,
10, 12, and 24 h after each dosing for 24 h dosing intervals. For
groups with 12 h dosing intervals, samples were collected at 2, 4,
6, 8, 10, and 12 h after each dosing. Samples of tissue-cage fluid
were clarified by centrifugation at 8900× g for 10 min and stored
at−20◦C until analyzed.
Cefquinome concentrations in tissue-cage fluid were
determined by HPLC-MS/MS (Agilent Technologies, USA;
Zhang B.X. et al., 2014). Briefly, after thawing, each sample
(200 µL) including blank sample was added to the same volume
acetonitrile for deproteinization, and then was clarified by
centrifugation. Two-hundred microliters clear supernatant
and 800 µL water were mixed and then transferred to an
HPLC-MS/MS vial. A calibration curve was made by adding
a known amount of cefquinome to blank tissue-cage fluid
over a concentration range of 0.005–3.000 µg/mL. All assays
were made in triplicate and the correlation coefficient for the
calibration curves were always ≥0.99.
Quantification of the Antimicrobial Effect
and Susceptibility Changes of S. aureus
to Cefquinome
Multiple samples (1 mL) were collected from the Wiﬄe ball
in each rabbit daily before, during the treatment (after every
administration), and 24 and 48 h after the termination of
treatment for one dosing daily groups, or 12 and 24 h for two
dosing daily group. To quantify the antimicrobial effect and the
mutant fraction, each sample (0.6 mL) was serially diluted with
the sterile normal saline and applied to MH agar either lacking
drug or containing cefquinome at 1×MIC of cefquinome. After
incubation for 24–48 h, colonies were calculated. The fraction
of mutant (%) was determined daily as the ratio of number
of colonies grown on 1 × MIC cefquinome-containing MH
agar to the number grown on drug-free agar. The low limit of
accurate detection was 200 CFU/mL. Other sample (0.4 mL) was
incubated overnight in drug-free MH broth and then the MIC
was determined as described above.
Resistant Strain Analysis
Resistant strains were chosen randomly from the 1 × MIC
of cefquinome-containing MH agar, and then passaged
five times on drug-free high salt mannitol medium agar.
The MICs of resistant strains were determined as described
above. Eight randomly selected resistant strains and one
original susceptible strain (bacteria were injected into
Wiﬄe ball in the beginning) were characterized by PFGE
using the CHEF-MAPPER System (Bio-Rad Laboratories,
Hercules, CA, USA), as described previously (McDougal et al.,
2003). The PFGE patterns were analyzed with BioNumerics
software (Applied Maths, Sint-Martens-Latem, Belgium)
using the Dice similarity coefficient with a cut-off at
90% of the similarity values to indicate identical PFGE
types.
Date Analysis
Pharmacokinetic parameters such as Cmax (the maximum
concentration) and AUC0−24 h or AUC0−12 h (24 or 12 h area
under the concentration–time curve) were calculated for each
tissue-cage, from 0 to 12 h or from 0 to 24 h after every drug
administration. AUC0−24 h or AUC0−12 h was calculated by
the trapezoidal rule. PK/PD parameters such as %T > MIC99
(the percentage of time that drug concentration remains above
the MIC99), %T > MPC (the percentage of time that drug
concentration remains above the MPC), Cmax/MIC99, Cmax/MPC
were calculated by using WinNonlin program (version 5.2,
Pharsight Corporation, Mountain View, CA, USA).
Fisher’s exact text was used for statistical analysis of the
PK/PD dates, with two groups of six infected but untreated
rabbits as a control. P values < 0.05 were considered statistically
significant.
RESULTS
MIC, MIC99, and MPC of Cefquinome for
S. aureus
The MICs of cefquinome against S. aureus ATCC 29213
on the agar plates and in the blank tissue-cage fluid were
both 0.5 µg/mL. The cefquinome MIC99 was 0.3 µg/mL.
The preliminary MPC of cefquinome and the exact MPC of
cefquinome were 2 and 1.6 µg/mL, respectively. All experiments
were performed in triplicate on different occasions.
The Pharmacokinetics of Cefquinome
Cefquinome concentrations in each tissue-cage of treatment
groups were determined and divided into eight groups as
shown in Figure 1 (A1–A8). Cefquinome concentrations shown
in each group were the mean values of concentrations from
every rabbit tissue-cage. The mean concentrations located in
different positions in the MSW: almost completely below the
lower window boundary (MIC99) (A1), across the MIC99
(A2–A4), completely inside the MSW (A5) and across the
upper window boundary (MPC) (A6–A8). The mean values of
AUC0−12 h or UC0−24 h and Cmax following multiple dosing
are shown in Table 1. The AUCs from 0 to 24 h and
from 0 to 12 h after every administration, as determined by
trapezoidal rules, ranged from 5.590 to 69.782µg·h/mL and
from 6.874 to 55.558µg·h/mL, respectively. The maximum
concentrations (Cmax) were calculated by WinNonlin program,
ranging from 0.231 to 2.154µg/mL and from 0.308 to
1.954µg/mL, respectively.
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FIGURE 1 | Effect of cefquinome concentration on mutant enrichment. 1, 3, 5, and 8 correspond to the four different treatment groups once daily for
5 days, 2, 4, 6, and 7 correspond to the four different treatment groups twice daily for 2.5 days, n is the animal number per group. In vivo simulated
pharmacokinetics (A) and the fraction of resistant mutant (B). Since the amount of bacteria for the group 32 mg/kg/24 h was below the minimum detection limit
(200 CFU/mL) on the seventh day (Figure 2), we cannot draw the mutant fraction (shown in dotted line).
TABLE 1 | The pharmacokinetic parameters of cefquinome following
multiple dose in rabbit tissue-cage infection model.
Cefquinome dose
(mg/kg of body weight)
24 h intervals 12 h intervals
AUC0−24 h
(µg·h/mL)
Cmax
(µg/mL)
AUC0−12 h
(µg·h/mL)
Cmax
(µg/mL)
4 5.590 0.231 6.874 0.308
8 18.398 0.454 16.468 0.618
16 30.846 1.091 22.070 1.304
24 ND ND 55.558 1.954
32 69.782 2.154 ND ND
The AUC0−24 h, AUC0−12 h, and Cmax were the mean values of multiple dose. ND,
not done.
The Antimicrobial Effect and
Susceptibility Changes
After a Wiﬄe ball was implanted subcutaneously into each rabbit
for a week, 4 of 38 rabbits died of infection. For the survivors,
no serious illness or distress was observed during the entire
experimental period when above 1010 CFU bacteria were injected
into the implanted ball. The effects of cefquinome on bacterial
survival in the tissue-cage model are shown in Figures 2 and 3.
Bacterial concentration remained constant (about 108 CFU/mL)
when rabbits were treated with sterile normal saline for five
times. Compared to the two saline groups, growth inhibition of
S. aureus was observed in groups at the dose of 4 mg/kg with
24 h intervals, bacterial numbers decreased slightly; for dose at 4,
8 mg/kg with 12 h intervals and at 8, 16 mg/kg with 24 h intervals,
bacterial numbers decreased obviously during the treatment,
but bacterial re-growth was observed after the termination of
treatment; for groups at the dose of 32 mg/kg with 24 h intervals
and 16, 24 mg/kg with 12 h intervals, bacterial numbers decreased
significantly and no bacterial re-growth was observed during the
whole observation period. Compared to the groups with one
dosing daily, bacterial numbers decreased more at the same dose
in the same time in the groups with two dosing daily. The reason
is that cefquinome concentration in the tissue-cage rose more in
the same time. For example, the bacterial numbers were about
105 CFU/mL on the fifth day and the highest concentration of
cefquinome was close to 0.8 µg/mL in the group of 8 mg/kg
with two dosing daily, but the bacterial numbers were about
107 CFU/mL and the highest concentration of cefquinome was
close to 0.3 µg/mL in the group of 8 mg/kg with one dosing daily.
Samples of S. aureus in tissue-cage fluid were checked for
susceptibility changes and mutant fraction after each treatment.
When drug concentrations were mostly below the MIC99
(Figure 1, Panel A1 and A2) or exceeded the MPC (Figure 1,
A8), no loss in susceptibility was observed, but mutant fraction
rose slightly and then remained unchanged (Figure 1, B1 and B2)
or decreased (Figure 1, B8). When drug concentration crossed
the MIC99 (Figure 1, A2–A4), completely fell inside the MSW
(Figure 1, A5), or crossed the MPC (Figure 1, A6 and A7),
the MICs increased to 1–2 µg/mL after the third or fourth
dose and the resistant strains were readily selected. The detailed
relationship between values of PK/PD parameters and selection
of resistance is shown in Table 2.
PK/PD Parameters and the Emergence
of Resistance
The correlation of MIC- and MPC-related PK/PD parameters
with the selection of resistance was displayed in Table 2.
%T > MIC99 is not only the main pharmacodynamic
parameter to measure the bactericidal activity of time-dependent
antibiotics but also the common parameter to restrict mutant
enrichment (Craig, 2007). Cefquinome is known as time-
dependent antibiotic. In all seven tissue-cages, when %T>MIC99
was < 70%, there was no loss of susceptibility. But, loss of
bacterial susceptibility occurred in 11 of 17 tissue-cages when
%T >MIC99 ≥ 70%. So %T >MPC is also the suitable parameter
with restricting mutant enrichment. The resistant strains were
selected in 20 of 22 tissue-cages when %T > MPC was < 55%.
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FIGURE 2 | Effect of cefquinome at different doses on bacterial survival in the tissue-cage model (24 h intervals). Three days after infection, different
doses (0, 4, 8, 16, and 32 mg/kg of body weight by use of intragluteal injection) of cefquinome were administered once daily for 5 days (indicated by the arrow). n is
the animal number per group.
FIGURE 3 | Effect of cefquinome at different doses on bacterial survival in the tissue-cage model (12 h intervals). Three days after infection, different
doses (0, 4, 8, 16, and 24 mg/kg of body weight by use of intragluteal injection) of cefquinome were administered twice daily for 2.5 days (indicated by the arrow). n
is the animal number per group.
In addition, other PK/PD parameters also indicated
statistically significant correlations with the selection of
resistance (Table 2). Mutant selection was promoted when
AUC/MIC99 fell between 61.33 h and 185.19 h or AUC/MPC
fell between 11.50 h and 34.72 h. In other forms, the MSWs
extended from 1.51 to 6.51 and from 0.28 to 1.22, respectively,
when Cmax/MIC99 and Cmax/MPC were considered.
Analysis of Resistant Strains
Nine S. aureus strains were determined by PFGE. A dendrogram
of percent similarity, calculated with Dice coefficients from the
PFGE data using a cut-off of 90%, revealed one major cluster of
strains. It means that the original susceptible strain (S. aureus
ATCC 29213) and the resistant strains were identical PFGE
types. Clearly, the resistant strains originated from the initial
population. The cefquinome MICs for resistant strains were both
1–2 µg/mL.
DISCUSSION
According to the MSW hypothesis, pathogens exposed to
continuous drugs would evolve into resistant bacteria if drug
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TABLE 2 | Correlation of PK/PD parameters with selection of resistance.
PK/PD
parameter
value
Groups Fraction of rabbits with
resistance bacteria
P
%T > MIC99
< 70% A1, A2 0/7 NA
≥ 70% A3–A8 11/17 0.009
%T > MPC
< 55%
55–58%
A1–A6A7 20/22
1/3
7.43× 10−5
0.33
≥58% A8 0/3 NA
AUC/MIC99 (h)
<61.33 A1, A2 0/7 NA
61.33–185.19 A3–A7 11/18 0.013
>185.19 A8 0/3 NA
AUC/MPC (h)
<11.5 A1, A2 0/7 NA
11.50–34.72 A3–A7 11/18 0.013
>34.72 A8 0/3 NA
Cmax/MIC99
<1.51 A1, A2 0/7 NA
1.51–6.51 A3–A6 13/15 0.0005
≥6.51 A7, A8 1/6 0.5
Cmax/MPC
<0.28 A1, A2 0/7 NA
0.28–1.22 A3–A6 13/15 0.0005
≥1.22 A7, A8 1/6 0.5
All parameters were calculated using total drug concentrations. NA, not applicable.
P values were calculated by Fisher’s exact test, with a set of six infected but
untreated rabbits used as a control, high values indicate no difference with the
control.
concentrations fell inside the MSW (Zhao and Drlica, 2001). In
this experiment, when the drug partly or wholly dropped into the
MSW, the fraction of mutants obviously increased (Figure 1, B3–
B6). The study proved that the boundaries of MSW determined
by in vitro agar plates or blank tissue-cage fluid were basically
consistent with those observed in in vivo model. It is also in
agreement with other studies (Croisier et al., 2004; Cui et al.,
2006; Almeida et al., 2007; Bourgeois-Nicolaos et al., 2007; Zhu
et al., 2012; Ni et al., 2014; Zhang B. et al., 2014). However,
Mei et al. (2015) found that the emergence of fosfomycin-
resistant mutations was found in vitro but not in vivo by using
rabbit infection model when the drug concentration fell into the
MSW.
From Figure 1 (B3–B6), Figures 2 and 3, we found that
bacterial numbers gradually decreased (except for 4 mg/kg with
24 h intervals) during the treatment (after every administration),
but the mutant fraction gradually increased, indicating the
resistant bacteria were gradually enriched and susceptible
bacteria partially were killed. After the termination of treatment,
the mutant fraction of one group on the sixth day is 100%
(Figure 1, B5) and the total amount of bacteria gradually
increased (Figure 2), indicating that bacteria in this group were
all resistant stains and they also grew gradually. Thus, the
selection of resistant bacteria for cefquinome arose from both
susceptible bacteria being killed and resistant bacteria re-growth.
Antimicrobial PK/PD parameters have been used to assess
the clinical effects and their potential in the prevention of
antibiotic resistance development (Leroy et al., 2012). In our
study, %T > MIC99 and %T > MPC ratios that protect against
the selection of resistant bacteria were < 70 and ≥ 58%,
respectively. Wang et al. (2014) found that %T > MIC target
to produce a bacteriostatic effect was 40–50% for cefquinome
against S. aureus in a Neutropenic Mouse Thigh Model. The
possible reasons for the different between the above two studies
may be that the different models were used and the latter did not
consider the emergence of resistant bacteria. Our result is similar
to Zhang B. et al. (2014), since they defined a %T >MPC ratio of
≥ 50% to prevent emergence of cefquinome-resistant Escherichia
coli in piglet tissue-cage model. Some investigators reported that
%T > MIC99 was the most-predictive parameter for the time-
dependent drugs for resistance suppression and AUC/MIC99 was
the most-predictive parameters for the concentration-dependent
drugs for resistance suppression in animal models (Jumbe et al.,
2003; Knudsen et al., 2003; Tam et al., 2009; Wang et al., 2014).
However, other investigators found that antimicrobial–pathogen
combinations in animal models, such as cefquinome against
Escherichia coli, vancomycin against S. aureus, linezolid against
Enterococcus faecalis (Bourgeois-Nicolaos et al., 2007; Zhu et al.,
2012; Zhang B. et al., 2014), still cannot reach a conclusion
that which pharmacodynamic parameters is the most-predictive
parameter. Our work also did not identify the most-predictive
parameter correlating with the resistance because only two dosing
frequencies were used. Because %T >MIC99 < 70% cannot keep
an effective antibacterial activity (Table 2, Figures 2 and 3) and
cefquinome is the time-dependent drug, %T > MPC may be the
best parameter for achieving an effective antimicrobial activity
and resistance suppression.
In this study, bacterial numbers decreased slightly for the dose
of 4 mg/kg at 12 h intervals or 24 h intervals, and bacterial
re-growth was observed after the termination of treatment,
suggesting 4 mg/kg maybe not sufficient to combat infection.
Intramuscular administration of cefquinome at the dose of
8–32 mg/kg bw exhibited excellent bactericidal effect against
S. aureus in tissue cage. However, due to the high MPC value
of cefquinome against S. aureus (1.6 µg/ml), concentrations
generated by those doses fell within the MSW, and dramatic
increases in the mutant fraction occurred in the treatment
group of 8–16 mg/kg bw. Although no resistant mutant was
observed for 32 mg/kg group, the dose seems to be too high,
compared to recommended dose of 1–3 mg/kg in veterinary
clinic. Considering the relevance for actual treatment, a strategy
is to keep %T > MPC ≥ 58% of the interval at the infected
site of the target animal for cefquinome against S. aureus. If the
doses exceeding MPC are unacceptably high, shorter intervals
such as 6 h or 8 h could be applied. Since the pharmacokinetic
profiles of cefquinome may vary in different animals, the optimal
dosage regimen must integrate pharmacokinetic parameters and
pharmacodynamic parameters from specific animal species. Of
course, other cefalosporins with narrow MSW may also be a good
choice.
Since we cannot guarantee the entire operation in a sterile
environment during animal experiment, it is necessary to identify
Frontiers in Microbiology | www.frontiersin.org 6 June 2016 | Volume 7 | Article 874
fmicb-07-00874 June 7, 2016 Time: 16:27 # 7
Xiong et al. PK/PD Parameters and Antibiotics Resistance
species relationship the original susceptible strain and the
selected resistant strains by PFGE. The results demonstrated
that these resistant bacteria originated from the cefquinome-
susceptible S. aureus population present in the site of local
infection.
In Gram-positive bacteria such as S. aureus, resistance to
β-lactam antibiotics occurs majorly as a result of modification of
penicillin-binding proteins (PBPs), with β-lactamase production
as a minor way. Since methicillin-resistant S. aureus (MRSA)
appeared at the start of the 1960s (Jevons et al., 1963),
MRSA has been the primary resistant in S. aureus. Because
MRSA is not only β-lactamase-mediated resistant bacteria, but
also contained a unique PBP (PBP 2a). The gene encoding
PBP2a is mecA and lies in a specificmobile genetic element
called the staphylococcal cassette chromosome mec (SCCmec)
that integrates into the chromosome using recombinases
(ccrAB or ccrC) carried on the SCCmec element itself
(Wang and Archer, 2010). However, expression of methicillin
resistance also associated with some other factors, such
as the FEM (factor essential for methicillin resistance) or
auxiliary factors (Komatsuzawa et al., 1999). Although these
mechanisms have already been discovered, the mechanisms
of cephalosporin against S. aureus are still very complex.
In the next experiment, we will carry out further study
to explore mutant genes causing the acquired cefquinome-
resistance.
In order to extend similar studies to other antimicrobial–
pathogen combinations, our study suggests that careful attention
should be paid to population size, experiment duration, the
choice of dosage, and the clear mechanism of drug resistance. The
mutants derived from wild-type bacteria was very low (10−6–
10−8; Drlica, 2001), when bacteria were exposed to drug, the
bacterial number must be sufficient large (e.g., > 108 CFU/mL)
to ensure that resistant bacteria emerged. Experiment must have
sufficiently duration to allow for the emergence of resistant
bacteria since their appearance may be delayed if there is a fitness
cost associated with resistance (Andersson and Levin, 1999).
Drug concentrations by the appropriate dose should fall into the
different positions of MSW (including outside MSW) as far as
possible. There must be a clear mechanism of drug resistance
to determine whether the resistant bacteria were caused by the
pressure effect of the drug selection.
We could conclude that the date obtained with cefquinome as
the time-dependent drug against S. aureus is in support of the
MSW hypothesis. Keeping drug concentrations above the MPC
for ≥58% of administration interval provides a strategy to keep
effective antibacterial activity and minimize the emergence of
resistance.
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